612 related articles for article (PubMed ID: 18162124)
21. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
22. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
Zacharoulis S; Levy A; Chi SN; Gardner S; Rosenblum M; Miller DC; Dunkel I; Diez B; Sposto R; Ji L; Asgharzadeh S; Hukin J; Belasco J; Dubowy R; Kellie S; Termuhlen A; Finlay J
Pediatr Blood Cancer; 2007 Jul; 49(1):34-40. PubMed ID: 16874765
[TBL] [Abstract][Full Text] [Related]
23. Current treatment approaches for mantle-cell lymphoma.
Witzig TE
J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
[TBL] [Abstract][Full Text] [Related]
24. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
25. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
[TBL] [Abstract][Full Text] [Related]
26. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
[TBL] [Abstract][Full Text] [Related]
29. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
Lenz G; Dreyling M; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
[TBL] [Abstract][Full Text] [Related]
31. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
34. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
35. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Soussain C; Hoang-Xuan K; Taillandier L; Fourme E; Choquet S; Witz F; Casasnovas O; Dupriez B; Souleau B; Taksin AL; Gisselbrecht C; Jaccard A; Omuro A; Sanson M; Janvier M; Kolb B; Zini JM; Leblond V;
J Clin Oncol; 2008 May; 26(15):2512-8. PubMed ID: 18413641
[TBL] [Abstract][Full Text] [Related]
36. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
37. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
McBride NC; Cavenagh JD; Newland AC; Lillington DM; Murrell C; Kelsey SM
Bone Marrow Transplant; 2000 Dec; 26(11):1165-72. PubMed ID: 11149726
[TBL] [Abstract][Full Text] [Related]
38. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
[TBL] [Abstract][Full Text] [Related]
39. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
Dreyling M; Hiddemann W
Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.
Thieblemont C; Antal D; Lacotte-Thierry L; Delwail V; Espinouse D; Michallet AS; Traulle C; Bouafia-Sauvy F; Giraud C; Salles G; Guilhot F; Coiffier B
Cancer; 2005 Oct; 104(7):1434-41. PubMed ID: 16104036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
